TradingView
DEXWireNews
2019년 8월 9일 오후 4시 42분

CLSD - Triple Bottom. Huge Analyst Prediction  

Clearside Biomedical, Inc.NASDAQ

설명

Clearside Biomedical, Inc. is a clinical stage biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. Its pipeline includes Suprachoroidal CLS-TA, Suprachoroidal, Suprachoroidal CLS-TA, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.

Average Recommendation: OVERWEIGHT

Average Target Price: 5.50

SHORT INTEREST
2.26M 07/15/19

P/E Current
-0.48

P/E Ratio (with extraordinary items)
-0.72

더보기